Onconova Therapeutics Inc. (ONTX) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Contrasting side by side

Since Onconova Therapeutics Inc. (NASDAQ:ONTX) and Jounce Therapeutics Inc. (NASDAQ:JNCE) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconova Therapeutics Inc. 1.31M 13.88 21.13M -16.25 0.00
Jounce Therapeutics Inc. 58.09M 2.41 34.70M -1.07 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Onconova Therapeutics Inc. -1,612.98% 0% -126.3%
Jounce Therapeutics Inc. -59.73% -28.4% -13.1%


Onconova Therapeutics Inc.’s Current Ratio and Quick Ratio are 2.8 and 2.8 respectively. The Current Ratio and Quick Ratio of its competitor Jounce Therapeutics Inc. are 3.1 and 3.1 respectively. Jounce Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Onconova Therapeutics Inc.

Institutional and Insider Ownership

Onconova Therapeutics Inc. and Jounce Therapeutics Inc. has shares held by institutional investors as follows: 54.1% and 81.1%. About 4.95% of Onconova Therapeutics Inc.’s share are held by insiders. Comparatively, 0.4% are Jounce Therapeutics Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Onconova Therapeutics Inc. -16.59% -37.59% -45.15% -56.3% -83.33% -83.91%
Jounce Therapeutics Inc. -10.19% -29.07% -46.04% -46.63% -73.2% -69.57%

For the past year Jounce Therapeutics Inc. has weaker performance than Onconova Therapeutics Inc.


On 7 of the 10 factors Jounce Therapeutics Inc. beats Onconova Therapeutics Inc.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companyÂ’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; a license agreement with SymBio Pharmaceuticals Limited; and a strategic collaboration with Cellectar Biosciences, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. The company is also developing JTX-4014, an anti-PD-1 antibody. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.